Date: 2014-12-18
Type of information: Company acquisition
Acquired company: Dutalys (Austria)
Acquiring company: Roche (Switzerland)
Amount: up to $ 488.75 million
Terms: * On December 18, 2014, Roche announced that it has agreed to acquire Dutalys, a privately held biotechnology company based in Vienna, Austria. Dutalys specializes in the discovery and development of fully human, bi-specific antibodies based on their proprietary DutaMab™ technology. The bi-specific antibodies developed with this platform are designed to provide novel, bestin-class molecules for several therapeutic areas. This deal further highlights Roche’s leadership in the development of therapeutic antibodies.
Under the terms of the agreement, Roche will make an upfront cash payment of $ 133.75 million to shareholders and make additional contingent payments of up to $ 355 million based on the achievement of certain predetermined milestones.
Details: A conventional bi-specific monoclonal antibody is a biotechnologically engineered artificial protein that is composed of fragments of two different monoclonal antibodies and consequently can bind to two different antigens. The DutaMab™ technology platform differs by enabling the development of fully human bi-specific antibodies where each arm of the antibody shows high affinity and simultaneous binding against both targets, excellent stability, and good manufacturing properties. This enables the treatment of disease mechanisms that could not be addressed with conventional bi-specific antibodies.
Related: Technology - Services
